R&G PharmaStudies Co. Ltd. A (301333) — Working Capital to Net Assets Ratio
R&G PharmaStudies Co. Ltd. A (301333) has a Working Capital to Net Assets ratio of 89.9% as of March 2026. Working capital of CN¥1.80 Billion (current assets of CN¥2.16 Billion minus current liabilities of CN¥359.47 Million) is measured against net assets of CN¥2.00 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. See R&G PharmaStudies Co. Ltd. A defensive interval ratio to measure how many days the company can operate on defensive assets alone.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
R&G PharmaStudies Co. Ltd. A Working Capital to Net Assets (2019–2025)
This chart shows how R&G PharmaStudies Co. Ltd. A's Working Capital to Net Assets ratio has evolved across 7 annual periods from 2019 to 2025. As of March 2026, the ratio stands at 89.9%, reflecting working capital of CN¥1.80 Billion against net assets of CN¥2.00 Billion CNY. For the complete balance sheet picture, see R&G PharmaStudies Co. Ltd. A balance sheet assets.
Annual Working Capital to Net Assets for R&G PharmaStudies Co. Ltd. A (2019–2025)
The table below presents the year-by-year Working Capital to Net Assets ratio for R&G PharmaStudies Co. Ltd. A from 2019 to 2025, covering 7 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. Check how resilient are R&G PharmaStudies Co. Ltd. A's assets to evaluate the company's liquid asset resilience ratio.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 89.6% | CN¥1.77 Billion | CN¥1.98 Billion | CN¥2.16 Billion | CN¥385.07 Million | ▼ -2.7 pp |
| 2024 | 92.3% | CN¥1.70 Billion | CN¥1.84 Billion | CN¥2.13 Billion | CN¥436.49 Million | ▼ -4.1 pp |
| 2023 | 96.4% | CN¥1.69 Billion | CN¥1.75 Billion | CN¥2.01 Billion | CN¥314.36 Million | ▲ +0.5 pp |
| 2022 | 95.9% | CN¥1.53 Billion | CN¥1.59 Billion | CN¥1.81 Billion | CN¥280.52 Million | ▲ +11.2 pp |
| 2021 | 84.7% | CN¥370.68 Million | CN¥437.81 Million | CN¥605.11 Million | CN¥234.43 Million | ▲ +2.0 pp |
| 2020 | 82.7% | CN¥278.73 Million | CN¥336.98 Million | CN¥472.62 Million | CN¥193.89 Million | ▲ +0.5 pp |
| 2019 | 82.2% | CN¥205.23 Million | CN¥249.74 Million | CN¥400.83 Million | CN¥195.60 Million | — |